Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00093730 · ClinicalTrials.gov registry record · Phase 1
BMS-599626 in Treating Patients With Metastatic Solid Tumors
A Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT00093730: Completed Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific, sponsored by Jonsson Comprehensive Cancer Center.
NCT00093730 is a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific that has completed, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 9 participants, below the 501-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00093730, a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: BMS-599626 may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of BMS-599626 in treating patients with metastatic solid tumors.
Conditions Studied
Interventions
- DRUG BMS-59926
Study Locations (1)
California
- Jonsson Comprehensive Cancer Center at UCLA - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2004-08 |
| Phase | Phase 1 |
What the finished NCT00093730 record still lists
NCT00093730 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 501-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Unspecified Adult Solid Tumor, Protocol Specific appearing as the primary indexed condition, and to 1 intervention - of which BMS-59926 is the first listed.
NCT00093730 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00093730 about?
NCT00093730 is a clinical study titled "BMS-599626 in Treating Patients With Metastatic Solid Tumors". RATIONALE: BMS-599626 may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of BMS-599626 in treating patients with metastatic solid tumors.
What is the current status of trial NCT00093730?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2004-08.
What conditions does trial NCT00093730 study?
This clinical trial studies the following conditions: Unspecified Adult Solid Tumor, Protocol Specific.
What interventions are being tested in trial NCT00093730?
The interventions under investigation include: BMS-59926 (DRUG).
Who is sponsoring clinical trial NCT00093730?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00093730 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Unspecified Adult Solid Tumor, Protocol Specific
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00093730's enrollment target sits among peer trials
9 83rd of 83 higher than 1 of 83 other Unspecified Adult Solid Tumor, Protocol Specific trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Unspecified Adult Solid Tumor, Protocol Specific trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists
ACTIVE NOT RECRUITING · Phase 1
-
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
COMPLETED · Phase 1
-
Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma
COMPLETED · Phase 1
-
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma
COMPLETED · Phase 1
-
Indole-3-Carbinol in Preventing Cancer in Healthy Participants
COMPLETED · Phase 1
-
Combination Chemotherapy With or Without Filgrastim in Treating Patients With Advanced Solid Tumors
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia